Pulmonary Cell News Volume 5.00 | Jan 7 2016

Bixin Protects Mice against Ventilation-Induced Lung Injury in an NRF2-Dependent Manner
In vitro, bixin was found to activate the NRF2 signaling pathway through blockage of ubiquitylation and degradation of NRF2 in a KEAP1-C151 dependent manner; intraperitoneal injection of bixin led to pulmonary upregulation of the NRF2 response in vivo. [Sci Rep] Full Article

Mesenchymal Stem Cells Protect from Hypoxia-Induced Alveolar Epithelial-Mesenchymal Transition
The authors investigated whether human mesenchymal stem cells would prevent epithelial-mesenchymal transition induced by hypoxia in primary rat alveolar epithelial cells. [Am J Physiol Lung Cell Mol Physiol] Abstract

Aeroallergen Der p 2 Induces Apoptosis of Bronchial Epithelial BEAS-2B Cells via Activation of Both Intrinsic and Extrinsic Pathway
Investigators showed that recombinant Der p 2 inhibited cell growth and induced apoptosis of human bronchial epithelial cell BEAS-2B. [Cell Biosc] Full Article

K_Ca3.1 K⁺ Channel Expression and Function in Human Bronchial Epithelial Cells
Researchers assessed whether primary human bronchial epithelial cells (HBECs) express the K_Ca3.1 channel and its role in HBEC function. Primary HBECs from the airways of healthy and asthmatic subjects, SV-transformed BEAS-2B cells and the neoplastic H292 epithelial cell line were studied. [PLoS One] Full Article

Brominated Flame Retardants, Hexabromocyclododecane and Tetrabromobisphenol A, Affect Proinflammatory Protein Expression in Human Bronchial Epithelial Cells via Disruption of Intracellular Signaling
Hexabromocyclododecane exposure significantly increased the expression of intercellular adhesion molecule-1 and the production of interleukin-6 and -8 in human bronchial epithelial cells. [Toxicol In Vitro] Abstract

LUNG CANCER

Synergistic Killing of Human Small Cell Lung Cancer Cells by the Bcl-2-Inositol 1,4,5-Trisphosphate Receptor Disruptor BIRD-2 and the BH3-Mimetic ABT-263
Scientists report for the first time that Bcl-2-IP3 receptor disruptor-2 (BIRD-2), a decoy peptide that binds to the BH4 domain of Bcl-2 and prevents Bcl-2 interaction with inositol 1,4,5-trisphosphate receptors, induces cell death in a wide range of small cell lung cancer lines, including ABT-263-resistant lines. [Cell Death Dis] Full Article

Expression of MicroRNA-452 via Adenoviral Vector Inhibits Non-Small Cell Lung Cancer Cells Proliferation and Metastasis
The authors identified how miR-452 acts in regulating non-small cell lung cancer (NSCLC) proliferation and metastasis. Expression of miR-452 via adenoviral vector inhibits the proliferation, invasion, and migration of NSCLC cells A549 or H460. [Tumor Biol] Abstract

The Attenuation of Epithelial to Mesenchymal Transition and Induction of Anoikis by Gigantol in Human Lung Cancer H460 Cells
Investigators demonstrated for the first time that gigantol significantly decreases lung cancer cells’ viability in a detached condition through anoikis and anchorage-independent assays. [Tumor Biol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.

OSE Pharma Announces Initiation of Its Pivotal Phase III Trial of Tedopi^® in Non-Small Cell Lung Cancer
OSE Pharma SA announced the initiation of its registration clinical trial named “Atalante 1”. This trial evaluates Tedopi^®, the company’s lead product for advanced non-small cell lung cancer. [OSE Pharma SA (Business Wire)] Press Release

Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase II Trial In Non-Small Cell Lung Cancer (NSCLC)
Mirati Therapeutics, Inc. announced that the Phase II clinical trial of glesatinib has commenced. [Mirati Therapeutics, Inc.] Press Release

Merrimack Amends MM-121 Phase II Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
Merrimack Pharmaceuticals, Inc. announced it filed an amendment to its ongoing Phase II clinical study of MM-121 in patients with heregulin-positive non-small cell lung cancer with the U.S. Food and Drug Administration. [Merrimack Pharmaceuticals, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

NEW Postdoctoral Research Fellow – Epigenetics/Systems Biology (National Heart, Lung, and Blood Institute)

NEW Postdoctoral Positions – Regenerative Biology and Medicine (Helmholtz Zentrum München)

NEW Postdoctoral Position – Molecular Cancer Cell Biology (Oslo University Hospital)

Professor – Precision Cancer Medicine (German Cancer Research Center)

PhD Positions – Heart and Lung Research (Max Planck Institute for Heart and Lung Research)

Postdoctoral Positions – Lung Cancer Research (University of Texas)

PhD Studentships – Cancer and Allergy (University of Salzburg)

Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Postdoctoral Fellow – Cancer Biology (Cold Spring Harbor Laboratory)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.